Penguin On Site | Exploring Pharmaceutical AI with Tencent Cloud and Opening New Horizons for Industry Digitalization
Article images may contain Chinese text.

On May 21, 2025, Weiming Penguin Co-founder and President Teresa and her team were invited to attend the “2025 Tencent Cloud AI Industry Application Summit” in Beijing. As a member company of the inaugural Tencent Hunyuan Large Model Bootcamp, Weiming Penguin took an active part in the summit, exploring innovative applications of AI technology in pharmaceuticals and healthcare together with Tencent.


With “Connecting Health” as its mission, Weiming Penguin is committed to building a digital ecosystem for the pharmaceutical and healthcare industry. Its founding team graduated from Peking University, while its technological roots trace back to Tencent. In the company’s name, “Weiming” symbolizes Peking University’s humanistic spirit, while “Penguin” represents Tencent’s technological strength. Together, they embody an approach that uses the twin drivers of humanistic values and technology to advance the pharmaceutical industry’s digital transformation. Drawing on years of experience in the pharmaceutical industry, Weiming Penguin leverages the strengths of Tencent’s AI foundation to continue upgrading its big data products and digital solutions. By precisely addressing industry challenges such as adapting to policy requirements and improving marketing efficiency, it helps pharmaceutical companies build new, data-driven growth trajectories.


At the summit, Tencent Cloud unveiled its agent development platform (TCADP), integrating technologies including the Hunyuan large model and DeepSeek-R1/V3. It introduced core capabilities such as access to multiple models and low-code development, and announced that Hunyuan’s 3D scene model would soon be open-sourced. Tang Daosheng, Senior Executive Vice President of Tencent, proposed four acceleration strategies: “large models, agents, knowledge bases, and infrastructure.”

The Hunyuan large model is already widely used in healthcare. For example, Tencent Health’s AI navigation and consultation assistance service, powered by Hunyuan, has been deployed in nearly 10,000 medical institutions across China. It helps healthcare workers improve service efficiency and quality while also improving the patient experience. In healthcare, a health management agent—the AI Health Management Assistant—has also been introduced. It can automatically interpret health checkup reports, intelligently analyze users’ health status, and identify potential risks in a timely manner. The assistant can also use question-answering capabilities to explain abnormal indicators and ways to address them in depth, and develop personalized follow-up consultation and health management plans for users.


As an important partner in Tencent’s ecosystem, Weiming Penguin will build on Tencent Cloud’s agent development platform to further optimize applications for pharmaceutical scenarios. It will help knowledge bases evolve from “passive queries” to “proactive services,” empowering pharmaceutical companies’ digital operations.

As a leader in pharmaceutical digitalization with both a strong humanistic foundation and technological roots, Weiming Penguin will continue to draw on Tencent Cloud’s technology ecosystem to deepen innovation at the intersection of “data intelligence × pharmaceutical distribution.” It will help the industry achieve the goals of China’s Guiding Opinions on the High-Quality Development of the Pharmaceutical Distribution Industry During the 14th Five-Year Plan Period, making AI technology a core engine for enhancing the pharmaceutical industry’s value.
